ImmunityBio shares are trading higher on continued strength after the company on Thursday announced insurance coverage of ANKTIVA across multiple states with first commercial doses administered.
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio shares are trading higher following the announcement of insurance coverage for ANKTIVA across multiple states and the administration of the first commercial doses.
June 21, 2024 | 3:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunityBio shares are experiencing a boost due to the announcement of insurance coverage for ANKTIVA in multiple states and the administration of the first commercial doses.
The news of insurance coverage for ANKTIVA and the administration of the first commercial doses is a significant milestone for ImmunityBio. This development is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100